Table I.
Association between CCR9 and clinicopathological characteristics.
| Clinicopathological characteristic | Number of patients | CCR9 postivity [N, (%)] | χ2 | P-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 40 | 25 (62.50) | 0.330 | 0.566 |
| Female | 20 | 14 (70.00) | ||
| Age (years) | ||||
| ≤60 | 37 | 22 (59.46) | 1.302 | 0.254 |
| >60 | 23 | 17 (73.91) | ||
| Histology | ||||
| SCC | 25 | 12 (48.00) | 5.444 | 0.020 |
| AC | 35 | 27 (77.14) | ||
| Lymph node metastasis | ||||
| No | 15 | 4 (26.67) | 12.918 | <0.001 |
| Yes | 45 | 35 (77.78) | ||
| VEGF | ||||
| Positive | 31 | 25 (80.65) | 6.901 | 0.008 |
| Negative | 29 | 14 (48.28) | ||
| MMP-1 | ||||
| Positive | 36 | 27 (75.00) | 3.956 | 0.047 |
| Negative | 24 | 12 (50.00) | ||
| MMP-7 | ||||
| Positive | 33 | 29 (87.88) | 16.873 | <0.001 |
| Negative | 27 | 10 (37.04) |
SCC, squamous cell carcinoma; AC, adenocarcinoma; CCR9, CC chemokine receptor 9; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase.